VERU-111 analogue 13f is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities.

Vernakalant Hcl(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.

Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.

Verapamil is a CYP3A inhibitor.

VER-50589 is a potent HSP90 inhibitor with IC50 of 21 nM for HSP90β.

Venlafaxine Hydrochloride is a dual ST and SLC6A2 (serotonin and noradrenalin re-uptake) inhibitor that displays ~ 30-fold higher affinity for ST (SERT) (Ki = 82 nm) than SLC6A2 (NET) (Ki = 2480 nM).

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.

VEL-0230 (NC-2300) is a potent, selective cysteine Cathepsins inhibitor with IC50 of 284, 34.5 and 186 nM for Cat B, K and S, respectively.

Vecabrutinib (SNS-062) is a potent, reversible, non-covalent BTK inhibitor with IC50 of 2.9 and 4.4 nM for WT BTK and C481S BTK, respectively.

VDR 4-1 is a novel non-steroidal, small-molecule agonist of vitamin D receptor (VDR).

VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection.

VCE-004.3 (VCE004.3) is a novel semi-synthetic cannabidiol derivative behaving as a dual PPARγ/CB2 agonist and CB1 receptor modulator, binds and activates PPARγ (IC50=3.5 uM) and CB2 receptors (pKi=6.69) and antagonizes CB1 receptor (pKi=5.61).

VB-82252 is a highly potent, orally active inhibitor of C. difficile toxins TcdA and TcdB, potently inhibits UDP glucose hydrolysis activity of TcdB (IC50=32 nM).

Varenicline Hcl(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.

Vapreotide acetate is a synthetic analog of somatostatin for the treatment of variceal bleeding; also exhibits antitumor activity.

Vapendavir (BTA798) is a novel potent enteroviral capsid binder, inhibits EV71 replication of all isolates with mean EC50 of 0.7 uM.

Vanoxerine (GBR-12909, I-893, Boxeprazine) is a highly potent inhibitor of dopamine uptake in vitro in tissue slices obtained from rat neostriatum with IC50 of 40-50 nM, also inhibits norepinephrine uptake with IC50 of 560-2600 nM.

Valganciclovir (hydrochloride), the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir.

Valdecoxib (SC 65872) is a COX-2 selective inhibitor with an IC50 value of 5 nM.

Valategrast hydrochloride is a potent, α4β1 (VLA-4) and α4β7 dual antagonist..

Valategrast (R411), a small molecule antagonist of α4β1 integrin, represents a potential therapy for asthma

Valacyclovir is an antiviral agent that acts as a very potent inhibitor of viral DNA polymerase.

Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (5-HT2C) receptor-selective agonist with an EC50 of 8 nM.

V-116517 is a novel potent, selective, oral bioavailable TRPV1 antagonist with IC50 of 35.1 nM.

V-11-0711 (V-11 0711) is a novel potent and selective choline kinase alpha (ChoKα) inhibitor with IC50 of 20 nM, with 11 fold less activity against ChoKβ.

UU-T01 is a novel small-molecule inhibitor of β-catenin/Tcf4 protein-protein interaction with Ki of 3.14 uM, binds to β-catenin with Kd of 0.531 uM..

USP7/USP47 inhibitor is a potent and dual inhibitor of USP7/USP47 with IC50s of 0.42 uM(USP7) and 1.0 uM(USP47).

USP25 and 28 inhibitor AZ-2 is a potent, selective, dual USP25/28 inhibitor with IC50 of 0.9/0.9 uM, respectively.

USP10-IN-9 is a HBX19818 analog, selective USP10 inhibitor with IC50 similar to HBX19818, but does not inhibit USP7 (IC50>100 uM)..